Late-onset neonatal infections and bacterial multidrug resistance.
Journal
Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo
ISSN: 1984-0462
Titre abrégé: Rev Paul Pediatr
Pays: Brazil
ID NLM: 9109353
Informations de publication
Date de publication:
29 May 2023
29 May 2023
Historique:
medline:
1
6
2023
pubmed:
31
5
2023
entrez:
31
5
2023
Statut:
epublish
Résumé
This study aims to describe bacterial and antimicrobial sensibilities in late-onset healthcare-associated infections (HAIs) with laboratory confirmation in a Neonatal Intensive Care Unit (NICU) of a public hospital in Ceará. This was a cross-sectional study conducted from January 2013 to December 2017. The bacterial types involved in late-onset HAIs, their sensitivity to antimicrobials, and their multidrug resistance were evaluated. The latter was classified according to the criteria revised by the Pan-American Health Organization as multidrug resistance (MDR), extended drug resistance (XDR), or pandrug resistance (PDR). The description of the variables was performed through proportions and frequency distribution depicted in tables. Of the 427 patients with late-onset HAIs, 47 (11.0%) had bacterial infections confirmed by blood cultures, and 7 (14.9%) had infections caused by MDR bacteria. Among the types of bacteria, 26 (55.3%) were Gram-negative bacteria, and 21 (44.7%) were Gram-positive bacteria. Among the Gram-negative bacteria, 92.3% (n=24) showed resistance to more than one antimicrobial, especially to ampicillin (81.2%), cefepime (33.1%), gentamicin (19.4%), and piperacillin/tazobactam (17.2%). Among the MDR ones, three cases had Klebsiella pneumoniae, and three had Pseudomonas aeruginosa, classified as two MDR and one XDR, and three XDR, respectively. Gram-positive resistance to penicillin was the most common one (80.0%), and approximately half of the strains being resistant to oxacillin. Susceptibility was high to vancomycin (97.5%), but one microorganism was resistant to oxacillin and vancomycin. The emergence of MDR strains is a reality in NICUs, carrying the risk of therapeutic failure and requiring continuous prevention protocols aimed at minimizing the risks of contamination by bacteria with high morbidity and mortality.
Identifiants
pubmed: 37255111
pii: S0103-05822023000100457
doi: 10.1590/1984-0462/2023/41/2022068
pmc: PMC10231417
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Vancomycin
6Q205EH1VU
Oxacillin
UH95VD7V76
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2022068Références
Rev Soc Bras Med Trop. 2019 Sep 05;52:e20190205
pubmed: 31508783
Diseases. 2018 Jan 30;6(1):
pubmed: 29385762
Int J Antimicrob Agents. 2017 Nov;50(5):629-639
pubmed: 28705671
Folia Med (Plovdiv). 2020 Dec 31;62(4):753-761
pubmed: 33415917
Iran J Pediatr. 2016 Jul 27;26(5):e5213
pubmed: 28203330
J Pediatric Infect Dis Soc. 2017 Sep 01;6(3):227-230
pubmed: 27302327
BMC Pediatr. 2018 May 23;18(1):172
pubmed: 29792168
Med Sci Monit. 2019 Nov 01;25:8213-8220
pubmed: 31675354
Braz J Infect Dis. 2008 Feb;12(1):75-9
pubmed: 18553019
Infect Control Hosp Epidemiol. 2016 Nov;37(11):1302-1309
pubmed: 27511591
Rev Panam Salud Publica. 2019 Aug 22;43:e65
pubmed: 31456820
Enferm Infecc Microbiol Clin. 2017 Oct;35(8):480-486
pubmed: 27469416
Rev Esc Enferm USP. 2010 Dec;44(4):1118-23
pubmed: 21337799
Rev Paul Pediatr. 2018 Apr-Jun;36(2):132-140
pubmed: 29412430
J Pediatric Infect Dis Soc. 2015 Mar;4(1):11-20
pubmed: 26407352
Pediatr Neonatol. 2018 Feb;59(1):35-41
pubmed: 28642139
Rev Bras Ter Intensiva. 2017 Jul-Sep;29(3):331-336
pubmed: 28876403